CHEMOCENTRYX, INC. (NASDAQ:CCXI) Files An 8-K Regulation FD Disclosure
Item 7.01
| 99.1 | ChemoCentryx Investor Presentation |
CHEMOCENTRYX, INC. (NASDAQ:CCXI) Files An 8-K Regulation FD Disclosure
ChemoCentryx, Inc. Exhibit
EX-99.1 2 d871668dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 New Ideas. Better Medicines. Presentation to Investors January 2020Exhibit 99.1 New Ideas. Better Medicines. Presentation to Investors January 2020 Forward‐Looking Statements This presentation contains forward‐looking statements that involve substantial risks and uncertainties. In some cases,…
To view the full exhibit click here
About CHEMOCENTRYX, INC. (NASDAQ:CCXI)
ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company’s pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases.
